{"classes":[{"categories":[{"measurements":[{"comment":"NA indicates that data could not be calculated because only one participant was analyzed.","groupId":"OG000","spread":"NA","value":"30.60"},{"groupId":"OG001","spread":"18.06","value":"14.82"},{"groupId":"OG002","spread":"56.24","value":"23.62"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"GSK3039294: n= 1, 10, 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.84","value":"3.581"},{"groupId":"OG001","spread":"21.78","value":"3.058"},{"groupId":"OG002","spread":"9.10","value":"2.476"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"title":"GSK2315698: n= 8, 16, 8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"description":"Blood samples were collected at specified time points for GSK3039294 and GSK2315698. Cmax was determined using standard non-compartmental methods.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received a single dose of GSK3039294 (dose level 1) 200 mg capsules, orally, once on Day 1 and stayed in-house until Day 4 in cohort 1.","id":"OG000","title":"Part A: GSK3039294 200 mg"},{"description":"Participants received a single dose of GSK3039294 (dose level 2) 600 mg capsules, orally, once on Day 1 and stayed in-house until Day 4 in cohort 1. The remaining participants received the same dose of GSK3039294 (dose level 3) 600 mg, capsules, orally, once on Day 1 and stayed in-house until Day 4 in cohort 2. A washout period was maintained from Day 5 to 14 between two treatment cohorts.","id":"OG001","title":"Part A: GSK3039294 600 mg"},{"description":"Participants received a single dose of GSK3039294 (dose level 4) 1200 mg, capsules, orally, once on Day 1 and stayed in-house until Day 4 in cohort 2.","id":"OG002","title":"Part A: GSK3039294 1200 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). NA indicates that data could not be calculated because only one participant was analyzed.","reportingStatus":"POSTED","timeFrame":"Pre-dose, and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24 and 48 hours post-dose","title":"Part A: Maximum Observed Plasma Concentration (Cmax) of GSK3039294 and GSK2315698","type":"SECONDARY","unitOfMeasure":"ng/mL"}